Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Actelion highlights positive trends in first half of 2011

Actelion highlights positive trends in first half of 2011

25th July 2011

Actelion has outlined the positive developments it has noted in its business performance during the first half of the year.

During the six months ending on June 30th 2011, the company generated a net revenue total of 969.9 million Swiss francs (739.7 million pounds), with product sales increasing by ten percent year on year in local currency terms.

Chief executive officer Jean-Paul Clozel stated that the company's performance has been solid despite the impact of currency fluctuations of the Swiss franc on its figures, while expressing confidence that it will meet its targets for the year.

He also observed the progress made on the clinical development of products such as its new CRTH2 antagonist and multiple sclerosis treatment ponesimod, suggesting this will help it to expand beyond its core disease areas.

Otto Schwarz, chief operating officer of Actelion, added: "I am satisfied with the sound commercial performance in the first six months of 2011, especially considering the difficult currency and competitive environment."

Mr Schwarz was appointed to his current role last month as part of Actelion's current corporate restructuring, which is designed to improve leadership and governance standards.ADNFCR-8000103-ID-800632365-ADNFCR

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.